FDAnews
www.fdanews.com/articles/98110-teva-receives-favorable-court-decision-regarding-generic-famvir

Teva Receives Favorable Court Decision Regarding Generic Famvir

September 6, 2007

Teva Pharmaceutical Industries announced that the U.S. District Court For the District of New Jersey has denied a motion filed by Novartis for a preliminary injunction related to Teva’s famciclovir tablets, a generic version of Novartis’ herpes treatment Famvir.

Teva’s abbreviated new drug application to market its famciclovir in 125-, 250- and 500-mg strengths has already been granted final approval by the FDA.

The brand product had annual U.S. sales of approximately $200 million for the twelve months ending June 30, based on IMS sales data.

Teva is currently involved in patent litigation with Novartis concerning this product. A trial date has not been set.